Adverse reactions in a large cohort of patients with inborn errors of immunity receiving intravenous immunoglobulin

Adverse reactions in a large cohort of patients with inborn errors of immunity receiving intravenous immunoglobulin

Copyright © 2021 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 230(2021) vom: 05. Sept., Seite 108826
1. Verfasser: Esmaeilzadeh, Hossein (VerfasserIn)
Weitere Verfasser: Askarisarvestani, Aida, Hosseini, Nazanin, Samimi, Sahar, Shafiei, Alireza, Mahdaviani, Seyed Alireza, Eslami, Narges, Chavoshzadeh, Zahra, Fallahi, Mazdak, Khakbazanfard, Nasrin, Shabestari, Mahnaz Sadeghi, Aleyasin, Soheila, Nabavizadeh, Seyed Hesamedin, Cheraghi, Taher, Kalantari, Arash, Ahmadiafshar, Akefeh, Safari, Mojgan, Eslamian, Mohammad Hossein, Molatefi, Rasol, Shirkani, Afshin, Heidarzadeh Arani, Marzieh, Tavakol, Marzieh, Bemanian, Mohammad Hassan, Arshi, Saba, Nabavi, Mohammad, Shokri, Sima, Shahhosseini, Babak, Mortazavi, Negar, Nakhaei, Pooria, Nazari, Farzad, Fallahpour, Morteza, Ahanchian, Hamid, Moazzen, Nasrin, Khoshkhui, Maryam, Motlagh, Ahmad Vosughi, Aghamohammadi, Asghar, Abolhassani, Hassan, Yazdani, Reza, Rezaei, Nima
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2021
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Multicenter Study Research Support, Non-U.S. Gov't Adverse reaction Inborn errors of immunity Intravenous immunoglobulins Iran Primary immunodeficiencies Immunoglobulins, Intravenous
LEADER 01000naa a22002652 4500
001 NLM329619381
003 DE-627
005 20231225205515.0
007 cr uuu---uuuuu
008 231225s2021 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2021.108826  |2 doi 
028 5 2 |a pubmed24n1098.xml 
035 |a (DE-627)NLM329619381 
035 |a (NLM)34418548 
035 |a (PII)S1521-6616(21)00163-7 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Esmaeilzadeh, Hossein  |e verfasserin  |4 aut 
245 1 0 |a Adverse reactions in a large cohort of patients with inborn errors of immunity receiving intravenous immunoglobulin 
264 1 |c 2021 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 13.09.2021 
500 |a Date Revised 13.09.2021 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2021 Elsevier Inc. All rights reserved. 
520 |a BACKGROUND: Intravenous immunoglobulins (IVIg) are the major treatment in inborn errors of immunity (IEI) disorders; However, IVIg infusions show some adverse effects. We aimed to assess the adverse reactions of IVIg infusions 
520 |a METHODS: Data of IVIg infusions in IEI patients were collected from 2011 to 2021. Totally, 363 IEI patients received IVIg regularly in Iran entered the study. The adverse reactions are classified regarding their severity and chronicity 
520 |a RESULTS: 22,667 IVIg infusions were performed in the study. 157 patients (43.2%) and 1349 (5.9%) infusions were associated with at least one type of adverse reaction. The highest rates of adverse reactions were seen in severe combined immunodeficiency. Myalgia, chills, headache, fever, and hypotension were the most frequent adverse effects of IVIg 
520 |a CONCLUSION: The reactions affect almost half of the patients mainly in the first infusions which necessitate the close observation of IEI patients receiving IVIg 
650 4 |a Journal Article 
650 4 |a Multicenter Study 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Adverse reaction 
650 4 |a Inborn errors of immunity 
650 4 |a Intravenous immunoglobulins 
650 4 |a Iran 
650 4 |a Primary immunodeficiencies 
650 7 |a Immunoglobulins, Intravenous  |2 NLM 
700 1 |a Askarisarvestani, Aida  |e verfasserin  |4 aut 
700 1 |a Hosseini, Nazanin  |e verfasserin  |4 aut 
700 1 |a Samimi, Sahar  |e verfasserin  |4 aut 
700 1 |a Shafiei, Alireza  |e verfasserin  |4 aut 
700 1 |a Mahdaviani, Seyed Alireza  |e verfasserin  |4 aut 
700 1 |a Eslami, Narges  |e verfasserin  |4 aut 
700 1 |a Chavoshzadeh, Zahra  |e verfasserin  |4 aut 
700 1 |a Fallahi, Mazdak  |e verfasserin  |4 aut 
700 1 |a Khakbazanfard, Nasrin  |e verfasserin  |4 aut 
700 1 |a Shabestari, Mahnaz Sadeghi  |e verfasserin  |4 aut 
700 1 |a Aleyasin, Soheila  |e verfasserin  |4 aut 
700 1 |a Nabavizadeh, Seyed Hesamedin  |e verfasserin  |4 aut 
700 1 |a Cheraghi, Taher  |e verfasserin  |4 aut 
700 1 |a Kalantari, Arash  |e verfasserin  |4 aut 
700 1 |a Ahmadiafshar, Akefeh  |e verfasserin  |4 aut 
700 1 |a Safari, Mojgan  |e verfasserin  |4 aut 
700 1 |a Eslamian, Mohammad Hossein  |e verfasserin  |4 aut 
700 1 |a Molatefi, Rasol  |e verfasserin  |4 aut 
700 1 |a Shirkani, Afshin  |e verfasserin  |4 aut 
700 1 |a Heidarzadeh Arani, Marzieh  |e verfasserin  |4 aut 
700 1 |a Tavakol, Marzieh  |e verfasserin  |4 aut 
700 1 |a Bemanian, Mohammad Hassan  |e verfasserin  |4 aut 
700 1 |a Arshi, Saba  |e verfasserin  |4 aut 
700 1 |a Nabavi, Mohammad  |e verfasserin  |4 aut 
700 1 |a Shokri, Sima  |e verfasserin  |4 aut 
700 1 |a Shahhosseini, Babak  |e verfasserin  |4 aut 
700 1 |a Mortazavi, Negar  |e verfasserin  |4 aut 
700 1 |a Nakhaei, Pooria  |e verfasserin  |4 aut 
700 1 |a Nazari, Farzad  |e verfasserin  |4 aut 
700 1 |a Fallahpour, Morteza  |e verfasserin  |4 aut 
700 1 |a Ahanchian, Hamid  |e verfasserin  |4 aut 
700 1 |a Moazzen, Nasrin  |e verfasserin  |4 aut 
700 1 |a Khoshkhui, Maryam  |e verfasserin  |4 aut 
700 1 |a Motlagh, Ahmad Vosughi  |e verfasserin  |4 aut 
700 1 |a Aghamohammadi, Asghar  |e verfasserin  |4 aut 
700 1 |a Abolhassani, Hassan  |e verfasserin  |4 aut 
700 1 |a Yazdani, Reza  |e verfasserin  |4 aut 
700 1 |a Rezaei, Nima  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 230(2021) vom: 05. Sept., Seite 108826  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:230  |g year:2021  |g day:05  |g month:09  |g pages:108826 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2021.108826  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 230  |j 2021  |b 05  |c 09  |h 108826